Hypersensitivity

Disease

Related News

FDA Approves Wakix for Cataplexy in Pediatric Narcolepsy Patients

The FDA has approved Harmony Biosciences' Wakix (pitolisant) for treating cataplexy in pediatric patients aged 6 years and older with narcolepsy, making it the first non-scheduled treatment for both pediatric and adult narcolepsy patients with or without cataplexy.

Related Clinical Trials

NCT ID Title Status Phase
NCT07352813

Intraosseous vs Infiltration Anesthesia in Molar-Incisor Hypomineralization (MIH) Children

RECRUITING NA
NCT07319273

Application of Child Life Services in Pediatric Skin Prick Test

NOT_YET_RECRUITING NA
NCT07257042

Oothpaste Containing 8% Arginine Compared to Colgate Cavity Protection Toothpaste in Reducing Dentinal Hypersensitivity

COMPLETED PHASE3
NCT07038746

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges

RECRUITING PHASE1
NCT06937697

Clinical of Hypersensitivity Reduction Efficacy on Two Toothpastes

COMPLETED PHASE3
NCT06538129

Assessment of Er:YAG Laser for the Control of Hypersensitivity During Tooth Whitening With Hydrogen Peroxide

NOT_YET_RECRUITING NA
NCT06463938

A Clinical Trial to Compare Lasotronix Alone or in Combination With CPP-ACP to Treat DH

RECRUITING NA
NCT06461143

Intraosseous Local Anesthesia System in Children With Molar Incisor Hypomineralization

SUSPENDED NA
NCT06445374

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges

COMPLETED PHASE1
NCT06392685

Composite Repair Using Silane Coupling Agent

NOT_YET_RECRUITING NA